Antibodies are part of the body’s natural defence against infection. They recognise harmful cells and destroy them. Monoclonal antibodies are man-made drugs designed to target certain types of cells. Monoclonal antibody treatments used for NHL are designed to target and destroy lymphocytes.
The treatment is given as a drip into a vein (intravenous infusion) and can usually be given to you as an outpatient.
The monoclonal antibody most commonly used to treat NHL is rituximab (Mabthera®). Other monoclonal antibodies that are sometimes used include ibritumomab tixuetan (Zevalin®) and tositumomab (BEXXAR®).